Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938255 | PMC |
| http://dx.doi.org/10.1038/s41416-023-02159-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications.
ESMO Open
August 2025
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Background: Despite the clinical impact of breast cancer (BC) brain metastases (BMs), their biological complexity remains poorly understood. We evaluated the genomic profile of BCBMs and compared it with paired primary BC samples to characterize biological changes during brain metastasization and their clinical impact in a retrospective real-world cohort.
Materials And Methods: Expression of 758 genes (BC360 Panel, nCounter), hormone receptor (HR) status, and human epidermal growth factor receptor type 2 (HER2) status were evaluated in BCBMs and matched primary BCs.
Affibody-based targeting agent I-YZ for HER2-positive ovarian cancer xenografts.
Front Med (Lausanne)
July 2025
Department of Nuclear Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Background: The human epidermal growth factor receptor 2 (HER2) affibodies are multifunctional tools that, when labeled with radioactive isotopes, hold significant potential for the diagnosis and treatment of tumors exhibiting HER2 overexpression. This research focuses on the development of I-labeled HER2 affibodies as targeted radionuclide therapy agents (TRNT) for HER2-positive Ovarian carcinoma.
Methods: The YZ affibody targeting HER2 was synthesized through genetic recombination.
Radiological signature of HER2-Positive gallbladder cancer: analysis of CT features.
Abdom Radiol (NY)
July 2025
Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Objective: This study aimed to identify distinctive computed tomography (CT) features associated with human epidermal growth factor receptor 2 (HER2) status in gallbladder cancer (GBC) that could serve as noninvasive imaging biomarkers.
Materials And Methods: This study included 213 patients with pathologically confirmed GBCs with availability of HER2 status (171 HER2-negative, 42 HER2-positive). Pre-treatment contrast-enhanced CT scans were evaluated by two radiologists blinded to HER2 status.
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer.
Breast Cancer
September 2025
Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Correction: Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib - Which One, How and For Whom?
Geburtshilfe Frauenheilkd
June 2025
Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany.
[This corrects the article DOI: 10.1055/a-2562-8469.].
View Article and Find Full Text PDF